Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatelizumab in moderate to severe ulcerative colitis
NCT01659138Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2012
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of vatelizumab in ulcerative colitis (UC), sponsored by Sanofi. Started Aug 2012; status: terminated.
02
Drugs
vatelizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01659138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01659138.